Table 1.
Demographic Information, Exposure, and Symptoms of Participants Testing at a Community Testing Site by Age Group, Wisconsin, November-December 2020
| No (%) |
||||
|---|---|---|---|---|
| Children (<18 yr), N = 225 | Adults (≥18 yr), N = 1885 | All Participants, N = 2110 | P Value | |
|
| ||||
| Age (yr) | ||||
| 5–8 | 42 (18.7) | – | 42 (2.0) | NA |
| 9–12 | 62 (27.6) | – | 62 (2.9) | |
| 13–15 | 66 (29.3) | – | 66 (3.1) | |
| 16–17 | 55 (24.4) | – | 55 (2.6) | |
| 18 to ≥65 | – | 1885 (100) | 1885 (89.3) | |
| Sex | ||||
| Male | 111 (49.3) | 794 (42.1) | 905 (42.9) | .10a |
| Female | 113 (50.2) | 1070 (56.8) | 1183 (56.1) | |
| Unknown | 1 (0.4) | 21 (1.1) | 22 (1.0) | |
| Race/ethnicity | ||||
| White, non-Hispanic | 187 (83.1) | 1689 (89.6) | 1867 (88.9) | <.01a |
| Hispanic/Latino | 16 (7.1) | 50 (2.7) | 66 (3.1) | |
| Asian, non-Hispanic | 5 (2.2) | 30 (1.6) | 35 (1.7) | |
| Black, non-Hispanic | 4 (1.8) | 17 (0.9) | 21 (1.0) | |
| American Indian/Alaska Native, non-Hispanic | 3 (1.3) | 10 (0.5) | 13 (0.6) | |
| Native Hawaiian/Pacific Islander, non-Hispanic | 0 (0) | 3 (0.2) | 3 (0.1) | |
| Unknown | 10 (4.4) | 86 (4.6) | 96 (4.5) | |
| Contact with a COVID-19 case in the past 14 days | ||||
| Yes | 112 (49.8) | 782 (41.5) | 894 (42.4) | .05 |
| Median (IQR) days since exposure | 4 (1–6) | 4 (1–6) | 4 (1–6) | |
| No | 80 (35.6) | 750 (39.8) | 830 (39.3) | |
| Don’t know/unknown | 33 (14.7) | 353 (18.7) | 386 (18.3) | |
| ≥1 symptom at time of testing | ||||
| Yes | 122 (54.2) | 1066 (56.6) | 1188 (56.3) | .74a |
| No | 99 (44.0) | 778 (41.3) | 877 (41.6) | |
| Unknown symptom status | 4 (1.8) | 41 (2.2) | 45 (2.1) | |
| CSTE clinical criteriab at time of testing | ||||
| Yes | 83 (36.9) | 844 (44.8) | 927 (43.9) | .06a |
| No | 138 (61.3) | 1000 (53.1) | 1138 (53.9) | |
| Unknown symptom status | 4 (1.8) | 41 (2.2) | 45 (2.1) | |
| Reported symptoms at time of testingc | ||||
| Congestion | 76 (62.3) | 592 (55.5) | 668 (56.2) | .15 |
| Sore throat | 43 (35.2) | 369 (34.6) | 412 (34.7) | .89 |
| Headache | 40 (32.8) | 466 (43.7) | 506 (42.6) | .02 |
| Cough | 29 (23.8) | 359 (33.7) | 388 (32.7) | .03 |
| Fatigue | 20 (16.4) | 368 (34.5) | 388 (32.7) | <.01 |
| Muscle aches | 15 (12.3) | 265 (24.9) | 280 (23.6) | <.01 |
| Chills | 14 (11.5) | 140 (13.1) | 154 (13.0) | .61 |
| Loss of smell | 12 (9.8) | 94 (8.8) | 106 (8.9) | .71 |
| Abdominal pain | 12 (9.8) | 44 (4.1) | 56 (4.7) | <.01 |
| Nausea | 11 (9.0) | 84 (7.9) | 95 (8.0) | .66 |
| Fever | 10 (8.2) | 85 (8.0) | 95 (8.0) | .93 |
| Shortness of breath | 9 (7.4) | 118 (11.1) | 127 (10.7) | .21 |
| Loss of taste | 6 (4.9) | 86 (8.1) | 6 (4.9) | .22 |
| Diarrhea | 5 (4.1) | 102 (9.6) | 107 (9.0) | .05 |
| Rigors | 1 (0.8) | 0 (0) | 1 (0.1) | .10a |
| Days since symptom onsetc | ||||
| 0–2 days since onset | 68 (55.7) | 458 (43.0) | 526 (44.3) | .03a |
| 3–5 days since onset | 33 (27.0) | 303 (28.4) | 336 (28.3) | |
| 6–7 days since onset | 4 (3.3) | 63 (5.9) | 67 (5.6) | |
| >7 days since onset | 5 (4.1) | 111 (10.4) | 116 (9.8) | |
| Unknown symptom onset | 12 (9.8) | 131 (12.3) | 143 (12.0) | |
Abbreviations: CSTE, Council of State and Territorial Epidemiologists; IQR, interquartile range; NA, not applicable.
a
Fisher exact P value.
b
CSTE clinical criteria is a surveillance case definition used within public health surveillance systems within the United States due to the nonspecific nature of symptoms associated with COVID-19.
c
Percentage denominator is participants reporting ≥1 symptom.
P value compares <18 years and ≥18 years.